Stephanie Diaz; Manager of Investor Relations; Viking Therapeutics Inc. Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc. Greg Zante ...

Welcome to the Viking Therapeutics First Quarter 2025 Financial ... Joining me today is Brian Lian, Viking's President and CEO; and Greg Zante, Viking's CFO. Before we begin, I'd like to caution ...

Discover key takeaways from Viking Therapeutics' Q1 2025 earnings call, including Phase 3 trial updates, financial performance, and obesity ...

Analysts Rahman and McCarthy hold a conference call with CFO Zante on April 30 hosted by Maxim Group.Stay Ahead of the Market: Discover ...

Viking Therapeutics has a 1 year low of $18.92 and a 1 year high of $81.86. The firm has a fifty day moving average price of $26.35 and a 200 day moving average price of $40.06.

Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.86. The company has a 50 day moving average price of $26.47 and a 200 day moving average price of $40.34. Insiders Place ...

All that being said, until the actual clinical trial data comes out, it's impossible to say for sure that the drug will be a success, or that Viking Therapeutics stock will go up as far and as ...

Viking Therapeutics reported a net loss of $0.41 per share for Q1 2025, missing analysts’ expectations of $0.33 loss per share. Following the earnings announcement, Viking Therapeutics’ stock ...